{
  "id": 13959443,
  "title": "Contineum drops 25% on mixed Bristol Myers IPF data; Stifel keeps Buy rating",
  "url": "https://urgent.news/2026/10/12/contineum-drops-25-on-mixed-bristol-myers-ipf-data-stifel-keeps-buy",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-12T13:06:24.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/stock-market-news/contineum-therapeutics-stock-surges-on-bristol-myers-trial-win-4944087"
  },
  "original_language": "en",
  "account": null,
  "summary": "Contineum Therapeutics' shares experienced a 25% drop after Bristol Myers Squibb announced positive results from its Phase 3 ALOFT-IPF trial for its LPA1 antagonist, admilparant. Contineum's lead asset, PIPE-791, targets the same biological pathway as admilparant. While the 60mg dose showed a statistically significant reduction in forced vital capacity (FVC) compared to placebo after 52 weeks, the 120mg dose did not reach statistical significance. Stifel analyst Paul Matteis maintained a Buy rating on Contineum, emphasizing the net positive impact of the trial results on the company's underlying science and the validation of the LPA1 mechanism in IPF.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}